AR075139A1 - Compuestos biciclicos para la reduccion de la produccion de beta-amiloide - Google Patents
Compuestos biciclicos para la reduccion de la produccion de beta-amiloideInfo
- Publication number
- AR075139A1 AR075139A1 ARP100100099A ARP100100099A AR075139A1 AR 075139 A1 AR075139 A1 AR 075139A1 AR P100100099 A ARP100100099 A AR P100100099A AR P100100099 A ARP100100099 A AR P100100099A AR 075139 A1 AR075139 A1 AR 075139A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- halo
- alkoxy
- heteroaromatic ring
- phenyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 7
- 125000005843 halogen group Chemical group 0.000 abstract 6
- 125000001072 heteroaryl group Chemical group 0.000 abstract 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 5
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 abstract 4
- -1 hydroxy, amino Chemical group 0.000 abstract 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 239000001301 oxygen Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Chemical group 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
Abstract
Compuestos que reducen la produccion del péptido beta-amiloide (beta-AP) y son utiles en el tratamiento de la enfermedad de Alzheimer y otros estados afectados por la produccion del péptido beta-amiloide (beta-AP). Reivindicacion 1: Un compuesto caracterizado porque tiene la formula (1) A-B-N(H)D-E, o una sal farmacéuticamente aceptable del mismo, en la que A es un anillo heteroaromático de cinco o seis miembros que contiene de uno a tres heteroátomos seleccionados independientemente entre nitrogeno, oxígeno y azufre; en el que dicho anillo heteroaromático está opcionalmente sustituido con uno o dos grupos seleccionados entre halo, halo-alquilo C1-6, hidroxi, amino, alcoxi C1-6 y alquilo C1-6; B está seleccionada entre fenilo y piridinilo, en el que el fenilo y el piridinilo están opcionalmente sustituidos con uno o dos sustituyentes seleccionados independientemente entre alcoxi C1-6, alquilo C1-6, alquilamino C1-3-alcoxi C1-6, ciano, dialquilamino C1-3-alcoxi C1-6, halo, halo-alcoxi C1-6, halo-alquilo C1-6, hidroxi, metilamino y amino; D está seleccionada entre el grupo de formulas (2) en las que ôla línea zig-zagö indica el punto de union al átomo de nitrogeno de la molécula de partida y öla doble línea zig-zagô indica el punto de union al resto ôEö; Ra está seleccionada entre hidrogeno, alquilo C1-6, alcoxi C1-6, hidroxi, dimetilamino, amino, metilamino y bencilamino, en el que la parte fenilo del bencilo está opcionalmente sustituida con uno, dos o tres sustituyentes seleccionados independientemente entre alquilo C1-6, alcoxi C1-6, ciano, halo, halo-alcoxi C1-6 y halo-alquilo C1-6; cada Rb está seleccionada independientemente entre hidrogeno, alcoxi C1-6, alquilo C1-6, alquilamino C1-6, amino, dialquilamino C1-6, halo, hidroxi y resto de formula (3) en la que n es 0 o 1 y ôla línea zig-zagö indica el punto de union al anillo; Rz es alquilo C1-6, y E está seleccionada entre alquilo C1-6, cicloalquilo C4-6, bencilo, fenilo y un anillo heteroaromático de cinco a seis miembros que contiene uno o dos átomos de nitrogeno, en el que cada uno del fenilo, la parte fenilo del bencilo y el anillo heteroaromático está opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados Independientemente entre alcoxi C1-6, alquilo C1-6, alquilsulfonilo C1-6, ciano, halo, halo-alcoxi C1-6, halo-alquilsulfonilo C1-6, halo-alquilo C1-6 y un anillo heteroaromático de cinco miembros que contiene uno, dos o tres átomos de nitrogeno, en el que el anillo heteroaromático está opcionalmente sustituido con un grupo alquilo C1-6.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14531909P | 2009-01-16 | 2009-01-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR075139A1 true AR075139A1 (es) | 2011-03-09 |
Family
ID=42061022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100100099A AR075139A1 (es) | 2009-01-16 | 2010-01-15 | Compuestos biciclicos para la reduccion de la produccion de beta-amiloide |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8349880B2 (es) |
| EP (1) | EP2379553B1 (es) |
| JP (1) | JP5638007B2 (es) |
| CN (1) | CN102356081B (es) |
| AR (1) | AR075139A1 (es) |
| ES (1) | ES2426023T3 (es) |
| TW (1) | TW201030002A (es) |
| WO (1) | WO2010083141A1 (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2011004680A (es) | 2008-11-06 | 2011-05-25 | Astrazeneca Ab | Moduladores de beta amiloide. |
| PA8854101A1 (es) | 2008-12-18 | 2010-07-27 | Ortho Mcneil Janssen Pharm | Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa |
| WO2010089292A1 (en) | 2009-02-06 | 2010-08-12 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc | Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators |
| TWI461425B (zh) | 2009-02-19 | 2014-11-21 | Janssen Pharmaceuticals Inc | 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類 |
| AU2010262036B2 (en) | 2009-05-07 | 2014-10-30 | Cellzome Limited | Novel substituted indazole and aza-indazole derivatives as gamma secretase modulators |
| EA021047B1 (ru) | 2009-07-15 | 2015-03-31 | Янссен Фармасьютикалз, Инк. | Замещенные производные триазола и имидазола в качестве модуляторов гамма-секретазы |
| US9145399B2 (en) * | 2010-01-15 | 2015-09-29 | Janssen Pharmaceuticals, Inc. | Substituted bicyclic triazole derivatives as gamma secretase modulators |
| CN103180326B (zh) | 2010-08-10 | 2015-06-10 | 武田药品工业株式会社 | 杂环化合物及其用途 |
| KR20130139895A (ko) * | 2010-09-02 | 2013-12-23 | 다케다 야쿠힌 고교 가부시키가이샤 | 경도인지 장애의 치료 또는 예방용 융합 트리아졸 |
| TW201309655A (zh) * | 2011-01-28 | 2013-03-01 | 必治妥美雅史谷比公司 | 降低β－類澱粉生成之化合物 |
| EP2688874B1 (en) | 2011-03-24 | 2015-03-04 | Janssen Pharmaceuticals, Inc. | 1,3,5-substituted 3-piperazine- or 3-piperidine-1,2,4-triazole derivatives as gamma secretase modulators for the treatment of alzheimer's disease |
| JP5767393B2 (ja) | 2011-03-31 | 2015-08-19 | ファイザー・インク | 新規二環式ピリジノン |
| TWI567079B (zh) | 2011-07-15 | 2017-01-21 | 健生醫藥公司 | 作為伽瑪分泌酶調節劑之新穎的經取代的吲哚衍生物 |
| EA027242B1 (ru) | 2012-05-16 | 2017-07-31 | Янссен Фармасьютикалз, Инк. | ЗАМЕЩЕННЫЕ 3,4-ДИГИДРО-2H-ПИРИДО[1,2-a]ПИРАЗИН-1,6-ДИОНОВЫЕ ПРОИЗВОДНЫЕ, ПРИМЕНИМЫЕ ДЛЯ ЛЕЧЕНИЯ (В ТОМ ЧИСЛЕ) БОЛЕЗНИ АЛЬЦГЕЙМЕРА |
| EP2687528A1 (en) | 2012-07-17 | 2014-01-22 | Ares Trading S.A. | Fused triazole derivatives as gamma secretase modulators |
| UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
| ES2608356T3 (es) | 2012-12-20 | 2017-04-10 | Janssen Pharmaceutica Nv | Novedosos derivados tricíclicos de 3,4-dihidro-2H-pirido[1,2-a]pirazin-1,6-diona como moduladores de la secretasa gamma |
| EP2945944B1 (en) | 2013-01-17 | 2016-11-09 | Janssen Pharmaceutica, N.V. | Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators |
| EP2958918B1 (en) * | 2013-02-21 | 2016-12-07 | Boehringer Ingelheim International GmbH | Dihydropteridinones ii |
| US9611254B2 (en) | 2013-06-04 | 2017-04-04 | Acturum Life Science AB | Triazole compounds and their use as gamma secretase modulators |
| ES2665421T3 (es) | 2013-06-04 | 2018-04-25 | Acturum Real Estate Ab | Compuestos de pirimidina y su uso como moduladores de la gamma secretasa |
| WO2014195322A1 (en) | 2013-06-04 | 2014-12-11 | Acturum Life Science AB | Triazole compounds and their use as gamma secretase modulators |
| US10562897B2 (en) | 2014-01-16 | 2020-02-18 | Janssen Pharmaceutica Nv | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators |
| TN2017000342A1 (en) | 2015-02-03 | 2019-01-16 | Pfizer | Novel cyclopropabenzofuranyl pyridopyrazinediones |
| WO2018001918A1 (en) | 2016-06-27 | 2018-01-04 | F. Hoffmann-La Roche Ag | Triazolopyridines as gamma-secretase modulators |
| AR109829A1 (es) * | 2016-09-29 | 2019-01-30 | Hoffmann La Roche | Derivados de piperidina puenteados |
| CN109641912B (zh) * | 2016-11-01 | 2021-10-29 | 豪夫迈·罗氏有限公司 | 二环杂芳基衍生物 |
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
| JP7248671B2 (ja) * | 2017-12-18 | 2023-03-29 | エフ． ホフマン－ラ ロシュ アーゲー | トリアゾロ－アゼピン誘導体 |
| US11370802B2 (en) * | 2018-01-22 | 2022-06-28 | Hoffmann-La Roche, Inc. | Triazolo-azepine derivatives |
| CA3149096A1 (en) | 2019-07-30 | 2021-02-04 | Eikonizo Therapapeutics, Inc. | Hdac6 inhibitors and uses thereof |
| JOP20220063A1 (ar) | 2019-09-16 | 2023-01-30 | Takeda Pharmaceuticals Co | مشتقات بيريدازين-3(2h)-أون ملتحمة بأزول |
| JP7777527B2 (ja) | 2019-11-29 | 2025-11-28 | エフ． ホフマン－ラ ロシュ アーゲー | （９Ｓ）－２－ブロモ－９－（２，３，４－トリフルオロフェニル）－６，７，８，９－テトラヒドロ－５Ｈ－［１，２，４］トリアゾロ［１，５－ａ］アゼピンの製造方法 |
| JP2025528048A (ja) * | 2022-08-08 | 2025-08-26 | 蘇州必揚医薬科技有限公司 | プロテインチロシンキナーゼ阻害剤およびその医療上の使用 |
| CN120324393B (zh) * | 2025-05-20 | 2025-11-04 | 广东海洋大学 | (2,4-二氯苯基)甲基硫基甲烷脒及其盐的用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007102580A1 (ja) * | 2006-03-09 | 2007-09-13 | Eisai R & D Management Co., Ltd. | 多環式シンナミド誘導体 |
| CN101809019A (zh) * | 2007-05-07 | 2010-08-18 | 先灵公司 | γ分泌酶调节剂 |
| MX2009012163A (es) | 2007-05-11 | 2009-12-01 | Hoffmann La Roche | Hetarilanilinas como moduladores para beta-amiloide. |
| US7935815B2 (en) * | 2007-08-31 | 2011-05-03 | Eisai R&D Management Co., Ltd. | Imidazoyl pyridine compounds and salts thereof |
| JP5433418B2 (ja) | 2007-08-31 | 2014-03-05 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 多環式化合物 |
| WO2009087127A1 (en) | 2008-01-11 | 2009-07-16 | F. Hoffmann-La Roche Ag | Modulators for amyloid beta |
| ES2428716T3 (es) | 2008-02-22 | 2013-11-11 | F. Hoffmann-La Roche Ag | Moduladores de beta-amiloide |
-
2009
- 2009-12-31 TW TW098146451A patent/TW201030002A/zh unknown
-
2010
- 2010-01-07 US US12/683,791 patent/US8349880B2/en active Active
- 2010-01-12 ES ES10700643T patent/ES2426023T3/es active Active
- 2010-01-12 EP EP10700643.9A patent/EP2379553B1/en not_active Not-in-force
- 2010-01-12 JP JP2011546297A patent/JP5638007B2/ja not_active Expired - Fee Related
- 2010-01-12 CN CN201080012637.2A patent/CN102356081B/zh not_active Expired - Fee Related
- 2010-01-12 WO PCT/US2010/020710 patent/WO2010083141A1/en not_active Ceased
- 2010-01-15 AR ARP100100099A patent/AR075139A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ES2426023T3 (es) | 2013-10-18 |
| EP2379553A1 (en) | 2011-10-26 |
| WO2010083141A1 (en) | 2010-07-22 |
| TW201030002A (en) | 2010-08-16 |
| EP2379553B1 (en) | 2013-06-26 |
| JP5638007B2 (ja) | 2014-12-10 |
| US20110015175A1 (en) | 2011-01-20 |
| CN102356081A (zh) | 2012-02-15 |
| JP2012515205A (ja) | 2012-07-05 |
| US8349880B2 (en) | 2013-01-08 |
| CN102356081B (zh) | 2014-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR075139A1 (es) | Compuestos biciclicos para la reduccion de la produccion de beta-amiloide | |
| AR077434A1 (es) | Compuestos para la reduccion de produccion de beta - amiloide | |
| EA201001682A1 (ru) | Производные фенил- и бензодиоксинилзамещенных индазолов | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| PE20140863A1 (es) | Compuestos de benceno sustituidos con arilo o heteroarilo | |
| EA200970510A1 (ru) | Гетеромоноциклическое соединение и его применение | |
| UY30414A1 (es) | Metano sulfonatos, propano-1-sulfonatos y ciclopropan sulfonatos sustituidos con [2,3,4,8-tetrahidroimidazo-[1,5-al-pirimidin-8-il]-fenilo, composiciones farmacéuticas conteniéndolos y aplicaciones. | |
| AR078542A1 (es) | Moduladores de gpr40 de pirrolidina | |
| AR049291A1 (es) | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso | |
| AR053092A1 (es) | Compuestos derivados de acido fenoxiacetico y compuestos intermediarios de sintesis | |
| AR068115A1 (es) | Derivado del acido pirazolcarboxilico metodo de produccion del mismo y fungicida | |
| EA201200669A1 (ru) | ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα | |
| PE20201165A1 (es) | Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| EA200800760A1 (ru) | ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα | |
| EA201001013A1 (ru) | Бис(сульфониламино)производные для применения в терапии | |
| HUP0401784A2 (hu) | Heterobiciklikus szerkezetû virális polimeráz inhibitorok, eljárás az elõállításukra, köztitermékek és ezeket tartalmazó gyógyszerkészítmények | |
| HRP20120323T1 (en) | Diarylhydantoin compounds | |
| AR086538A1 (es) | COMPUESTOS PARA REDUCIR LA PRODUCCION DE b-AMILOIDE | |
| CO6180449A2 (es) | Quinazolinonas y naftiridinonas que incluyen un grupo n-(bifenil-4-ilmetil-n-(piperidin-4-il)acetamida sustituida, utiles para el tratamiento de aterosclerosis | |
| AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
| AR061371A1 (es) | Amino - imidazolonas y su uso como medicamento para la enfermedad de alzheimer y otras enfermedades neurodegenerativas. | |
| AR066103A1 (es) | Derivados de triazolopiridin - carboxamidas, su preparacion y su aplicacion en terapeutica | |
| PE20141698A1 (es) | Proceso para la preparacion de derivados de l-alanina protegidos | |
| EA201300250A1 (ru) | Оксадиазольные ингибиторы продуцирования лейкотриена | |
| AR073043A1 (es) | Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |